BSX

Summary

Sell BSX into strength using staged limits toward overhead resistance rather than panic selling an unfinished weak bar. Our analysis is to reduce and exit longs, avoid bottom fishing and avoid adding new medtech beta. Position sizing should stay small given volatility around 4% of price, with a wider cushion and light recent volume versus a heavy prior supply day. Stay out on settled closes below support and the yearly low; only a reclaim of short term averages on full volume would force a cover reassessment. Horizon is 5 trading days for alpha versus SPY with a multi week information vacuum until Oct 28.

The case

1. Fundamentals confirm a full year miss, not a delay. A cybersecurity filing signals BSX is unlikely to meet Q3 and full year sales growth and adjusted EPS because it cannot ship and fill orders, with no update until Oct 28. Our analysis treats this as guided miss and share loss rather than deferred sales, as a large peer raises while BSX warns.

2. Technicals are broken and overhead is heavy. The stock trades below short term, medium term and long term moving averages with the long term average trending down. Momentum is negative with a widening negative histogram and no bullish divergence, and relative strength is not washed out. A heavy early September supply bar capped the subsequent bounce, leaving average holders underwater and overhead resistance intact after a year long decline with heavy distribution.

3. Positioning favors fading rallies. Options show elevated put skew and high implied volatility around 60% signaling dealer pressure, while social sentiment is frustrated after a sharp drop with an insider purchase now overhead. A sell side firm cut its target, and healthcare fell around -2.5% on the day on fearful readings from a market fear gauge, while healthcare is up around 25.7% over six months versus SPY up around 13.6%, proving BSX underperforms a strong tape.

4. Earnings quality is illusory and the balance sheet is stretched, supporting a Sell. Q1 net doubled on other non operating swings and tax benefits while operating income barely moved, so forward multiples and implied upside around 42% cannot be annualized. Q1 free cash was pressured by working capital drag and buyouts, with receivables and inventory growing faster than revenue at over 11.6%. Q2 revenue missed with diluted earnings down from normalized levels, intangibles exceed 57% of assets with large goodwill versus thin tangible book, leverage exceeds 50% with cash down year over year and restructuring charges pending from July 21. Segment combination obscures WATCHMAN and EP trends amid EP competition including Farapulse, China pricing pressure in urology, and WATCHMAN deceleration pushing recovery to 2028. The unfinished weak bar holds only around 4.5% above the yearly low with noise and low beta and margins around 23%, but patience risks dead money with gap risk and whipsaws at 60% volatility. Our plan is staged limits into resistance, not a market dump, requiring settled closes for any adds.

What would weaken it

• Bounce to overhead resistance squeezes staged short limits
• Reclaim of short term averages on full volume forces cover
• Low beta and 23% margins cushion downside in firm tape